Related references
Note: Only part of the references are listed.Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Francesca Conradie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid
Suha Kadura et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A revised biosynthetic pathway for the cofactor F420 in prokaryotes
Ghader Bashiri et al.
NATURE COMMUNICATIONS (2019)
A cautionary note on the mutation frequency in microbial research
Qi Zheng
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2018)
Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data
Dalin Rifat et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
Mamoru Fujiwara et al.
TUBERCULOSIS (2018)
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide
Adam N. Yadon et al.
NATURE COMMUNICATIONS (2017)
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
Si-Yang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis
Rokeya Tasneen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee
Harald Hoffmann et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
The Redox Cofactor F420 Protects Mycobacteria from Diverse Antimicrobial Compounds and Mediates a Reductive Detoxification System
Thanavit Jirapanjawat et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2016)
Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system
Elisa Schena et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions
Chris Greening et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2016)
Mutations in Genes for the F420 Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in Spontaneous In Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis
Hana L. Haver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson et al.
LANCET (2015)
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
Guido V. Bloemberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study
Selvakumar Subbian et al.
PLOS ONE (2015)
senX3-independent contribution of regX3 to Mycobacterium tuberculosis virulence
Dalin Rifat et al.
BMC MICROBIOLOGY (2014)
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Vija Skripconoka et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents
Meera Gurumurthy et al.
MOLECULAR MICROBIOLOGY (2013)
Rapid detection of multidrug-resistant Mycobacterium tuberculosis using the malachite green decolourisation assay
Ahmet Yilmaz Coban et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2013)
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Thomas R. Ioerger et al.
PLOS ONE (2013)
Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
Jamie Harper et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Biosynthesis of F0, Precursor of the F420 Cofactor, Requires a Unique Two Radical-SAM Domain Enzyme and Tyrosine as Substrate
Laure Decamps et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
Susan E. Cellitti et al.
STRUCTURE (2012)
PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Impact of fgd1 and ddn Diversity in Mycobacterium tuberculosis Complex on In Vitro Susceptibility to PA-824
Silke Feuerriegel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Variation among Genome Sequences of H37Rv Strains of Mycobacterium tuberculosis from Multiple Laboratories
Thomas R. Ioerger et al.
JOURNAL OF BACTERIOLOGY (2010)
Evaluation of Colorimetric Methods Using Nicotinamide for Rapid Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis
Niuris C. Mirabal et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Metabolic Engineering of Cofactor F420 Production in Mycobacterium smegmatis
Ghader Bashiri et al.
PLOS ONE (2010)
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates
Laura E. Via et al.
INFECTION AND IMMUNITY (2008)
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents
Julian G. Hurdle et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding
Ghader Bashiri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A common mechanism of cellular death induced by bactericidal antibiotics
Michael A. Kohanski et al.
CELL (2007)
Mycobacterium smegmatis mc2 155 fbiC and MSMEG_2392 are involved in triphenylmethane dye decolorization and coenzyme F420 biosynthesis
Denise Guerra-Lopez et al.
MICROBIOLOGY-SGM (2007)
Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis:: a systematic review and meta-analysis
Anandi Martin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice
Makoto Matsumoto et al.
PLOS MEDICINE (2006)
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
UH Manjunatha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis
S Tyagi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Application of oxidation-reduction assay for monitoring treatment of patients with pulmonary tuberculosis
P Farnia et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
EL Nuermberger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Identification of the 7,8-didemethyl-8-hydroxy-5-deazariboflavin synthase required for coenzyme F420 biosynthesis
DE Graham et al.
ARCHIVES OF MICROBIOLOGY (2003)
Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium bovis BCG
KP Choi et al.
JOURNAL OF BACTERIOLOGY (2001)
Structures of coenzyme F420 in Mycobacterium species
TB Bair et al.
ARCHIVES OF MICROBIOLOGY (2001)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
CK Stover et al.
NATURE (2000)
Share Paper
